- Home
- JNJ
JNJ
Johnson & Johnson
as 01-21-2025 4:00pm EST
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | N/A | IPO Year: | 1944 |
| Target Price: | $173.38 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 6.04 | EPS Growth: | -54.32 |
| 52 Week Low/High: | $140.68 - $168.85 | Next Earning Date: | 01-22-2025 |
| Revenue: | $87,696,000,000 | Revenue Growth: | 4.77% |
| Revenue Growth (this year): | 5.32% | Revenue Growth (next year): | 2.89% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WEINBERGER MARK A | JNJ | Director | Dec 12 '24 | Buy | $147.22 | 1,000 | $147,220.00 | 1,000 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
Johnson & Johnson Says Spravato Approved by US FDA as Monotherapy for Major Depressive Disorder
PR Newswire
a day ago
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
MT Newswires
a day ago
Barclays Adjusts Price Target on Johnson & Johnson to $159 From $160, Maintains Equalweight Rating
GuruFocus.com
a day ago
The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value
Simply Wall St.
a day ago
Here's Why Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt Responsibly
Motley Fool
a day ago
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Motley Fool
a day ago
Can the 8 Worst-Performing Dow Jones Stocks in 2024 Beat the S&P 500 in 2025?
Motley Fool
a day ago
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.